loader
Please Wait
Applying Filters...

Annual Sales of Triheptanoin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 10Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Dojolvi

02 3UX007

PharmaCompass

01

Brand Name : UX007

Triheptanoin

arrow
Discovery on Target
Not Confirmed

Brand Name : UX007

arrow
Discovery on Target
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2019 Revenue in Millions : 3

2018 Revenue in Millions : 1

Growth (%) : 163

blank

02

Brand Name : UX007

Triheptanoin

arrow
Discovery on Target
Not Confirmed

Brand Name : UX007

arrow
Discovery on Target
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2020 Revenue in Millions : 13

2019 Revenue in Millions : 3

Growth (%) : 295

blank

03

Brand Name : UX007

Triheptanoin

arrow
Discovery on Target
Not Confirmed

Brand Name : UX007

arrow
Discovery on Target
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2021 Revenue in Millions : 40

2020 Revenue in Millions : 13

Growth (%) : 204

blank

04

Brand Name : Dojolvi

Triheptanoin

arrow
Discovery on Target
Not Confirmed

Brand Name : Dojolvi

arrow
Discovery on Target
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Diseases

Currency : USD

2022 Revenue in Millions : 56

2021 Revenue in Millions : 40

Growth (%) : 41

blank

05

Brand Name : Dojolvi

Triheptanoin

arrow
Discovery on Target
Not Confirmed

Brand Name : Dojolvi

arrow
Discovery on Target
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Diseases

Currency : USD

2023 Revenue in Millions : 71

2022 Revenue in Millions : 56

Growth (%) : 27

blank